Objective: Implantable cardioverter-defibrillators (ICDs) prevent arrhythmic death, but do not modify disease progression. The prevalence of persistent cardiovascular risk factors in patients receiving an ICD and their adherence to optimal pharmacological therapy at late follow-up is unknown. The aim of this study was to assess the prevalence of cardiovascular and specific sudden cardiac arrest (SCA) risk factors, and the pharmacological treatment in ICD recipients who survived SCA caused by ventricular fibrillation (VF).
Design: Cross-sectional study. A total of 100 consecutive ICD patients who survived SCA due to documented VF, not due to a transient or reversible cause or an arrhythmogenic disease, were interviewed and examined at the routine outpatient clinic.
Results: The mean age of the patients was 60 ± 11 years, and they were analysed at a median interval of 1092 days after SCA. The majority of patients had coronary artery disease. The New York Heart Association class at the time of implantation was ≥II in 62%. A single chamber device was used in 49% and a resynchronization device in 12%. At the routine control, the most prevalent risk factors were overweight or obesity (63%), hypertension (41%), and smoking (16%). Pharmacological therapy was suboptimal in 18 –32% of the patients. Eight per cent of the patients had known diabetes and 29% had elevated HbA1c levels. While only 7% had pre-existing overt heart failure, 43% had N-terminal pro-brain natriuretic peptide levels ≥100 pmol/l. High sensitivity C-reactive protein was ≥3 mg/l in 52% of the patients. Family history was positive for sudden cardiac death (SCD) in 46% of the patients.
Conclusions: Despite regular medical consultation, a large proportion of the patients had persistent cardiovascular risk factors and were often suboptimally treated. Unexpectedly, latent heart failure and unrecognized diabetes are observed in a large proportion of the patients, as well as elevated inflammatory markers. Genetic analysis may be rewarding, as 46% of the patients had a family history of SCD. Full medical attention, optimizing drug therapy, and counselling of these patients is necessary.
PrioriSGAliotEBlomstrom-LundqvistCBossaertLBreithardtGBrugadaP. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J2001; 22(16): 1374–1450.
2.
Bayes de LunaACoumelPLeclercqJF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J1989; 117(1): 151–159.
3.
ZhengZJCroftJBGilesWHMensahGA. Sudden cardiac death in the United States, 1989 to 1998. Circulation2001; 104(18): 2158–2163.
4.
SpauldingCMJolyLMRosenbergAMonchiMWeberSNDhainautJF. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med1997; 336(23): 1629–1633.
5.
Centers for Disease Control and Prevention (CDC). State-specific mortality from sudden cardiac death United States, 1999. MMWR Morb Mortal Wkly Rep2002; 51(6): 123–126.
6.
CupplesLAGagnonDRKannelWB. Long- and short-term risk of sudden coronary death. Circulation1992; 85(Suppl 1): I11–I18.
7.
WannametheeGShaperAGMacfarlanePWWalkerM. Risk factors for sudden cardiac death in middle-aged British men. Circulation1995; 91(6): 1749–1756.
8.
JouvenXDesnosMGuerotCDucimetièreP. Predicting sudden death in the population: the Paris Prospective Study I. Circulation1999; 99(15): 1978–1983.
9.
VaartjesIHendrixAHertoghEMGrobbeeDEDoevendansPAMosterdA. Sudden death in persons younger than 40 years of age: incidence and causes. Eur J Cardiovasc Prev Rehabil2009; 16(5): 592–596.
10.
The AVID Investigators. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol1999; 34(5): 1552–1559.
11.
CrandallBGMorrisCDCutlerJEKudenchukPJPetersonJLLiemLB. Implantable cardioverter-defibrillator therapy in survivors of out-of-hospital sudden cardiac death without inducible arrhythmias. J Am Coll Cardiol1993; 21(5): 1186–1192.
12.
WangTJLarsonMGLevyDBenjaminEJLeipEPOmlandT. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med2004; 350(7): 655–663.
13.
AlbertCMMaJRifaiNStampferMJRidkerPM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation2002; 105(22): 2595–2599.
14.
ZipesDPCammAJBorggrefeM. Buxton AE, Chaitman B, Fromer M, et al.; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association and the Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death–executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J2006; 27(17): 2099–2140.
15.
KannelWBCupplesLAD’AgostinoRBStokes3rdJ. Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham Study. Hypertension1988; 11(3 Pt 2): II45–II50.
16.
WeijenbergMPFeskensEJKromhoutD. Blood pressure and isolated systolic hypertension and the risk of coronary heart disease and mortality in elderly men (the Zutphen Elderly Study). J Hypertens1996; 14(10): 1159–1166.
17.
GoldenbergIMossAJMcNittSZarebaWDaubertJPHallWJ. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol2006; 17(9): 931–936.
18.
ExnerDVReiffelJAEpsteinAELedinghamRReiterMJYaoQ. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol1999; 34(2): 325–333.
19.
MitchellLBPowellJLGillisAMKehlVHallstromAPAVIDInvestigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol2003; 42(1): 81–87.
20.
De SutterJTavernierRDe BuyzereMJordaensLDe BackerG. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol2000; 36(3): 766–772.
21.
MaederMRickliHSticherlingCWidmerRAmmannP. Hypokalaemia and sudden cardiac death ⊟ lessons from implantable cardioverter defibrillators. Emerg Med J2007; 24(3): 206–208.
22.
SteinbergBABhattDLMehtaPoole-WilsonPAO'HaganPMontalescotG. Nine-year trends in achievement of risk factor goals in the US and Europe outpatients with cardiovascular disease. Am Heart J2008; 156(4): 719–727.
23.
CygankiewiczIGillespieJZarebaWBrownMWGoldenbergIKleinH. Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. Heart Rhythm2009; 6(4): 468–473.
24.
MadridAHPengJZamoraJMarínIBernalEEscobarC. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol2004; 27(10): 1405–1410.
25.
CrippsTRMalikMFarrellTGCammAJ. Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J1991; 65(1): 14–19.
26.
FarrellTGBashirYCrippsTMalikMPolonieckiJBennettED. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol1991; 18(3): 687–697.
27.
BlangyHSadoulNDoussetBRadauceanuAFayRAliotE. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace2007; 9(9): 724–729.
28.
TheunsDAMJSmithTSzili-torokTMuskens-HeemskerkAJanseP. Prognostic role of high-sensitivity C-reactive protein and B-type natriuretic peptide in implantable cardioverter-defibrillator patients. PACE2011DOI: 10.1111/j.1540-8159.2011.03289.x.
29.
SabatineMSMorrowDAJablonskiKARiceMMWarnicaJWDomanskiMJ. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation2007; 115(12): 1528–1536.
30.
FriedlanderYSiscovickDSWeinmannSAustinMAPsatyBMLemaitreRN. Family history as a risk factor for primary cardiac arrest. Circulation1998; 97(2): 155–160.
31.
DekkerLRBezzinaCRHenriquesJPTanckMWKochKTAlingsMW. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation2006; 114(11): 1140–1145.
